Lactobacillus paracasei compound beverage, preparation method and application of lactobacillus paracasei

By combining Lactobacillus paracasei with Chinese herbal medicines such as hawthorn and papaya, a sugar-free lactic acid bacteria compound beverage was developed, which solved the problem of the toxic side effects of existing blood lipid-lowering drugs on the human body, and achieved the reduction of blood lipids and regulation of liver fat. The effects of metabolic and intestinal flora diversity meet health and taste needs.

CN119014504AInactive Publication Date: 2024-11-26SOUTHWEST FORESTRY UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410895607.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-04
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing blood lipid-lowering drugs have toxic side effects on the human body and cannot effectively solve the problem of high prevalence of dyslipidemia in adults in China.

Method used

Lactica ibacillus paracasei SWFU-D16, which has a blood-lipid-lowering effect, was isolated from traditional fermented goat milk cakes and combined with Chinese herbal medicines such as hawthorn, papaya, prickly pear, black tea, etc., to develop a sugar-free lactic acid bacteria complex. Beverage, containing 20-50% Lactobacillus paracasei suspension and 50-80% plant extract, used to reduce the body's blood lipids.

Benefits of technology

This compound beverage not only reduces TC, TG and LDL-C in the serum, improves HDL-C, regulates liver fat metabolism, increases digestive tract mucosa thickness, and improves intestinal flora diversity, but also lowers blood lipid-lowering effect of Lactobacillus paracasei. It is stronger than traditional lactic acid strains, and the drink tastes better, is rich in nutrition, and meets health needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119014504A_ABST
    Figure CN119014504A_ABST
Patent Text Reader

Abstract

The invention discloses a lactobacillus paracasei compound beverage, a preparation method and application of lactobacillus paracasei. The beverage comprises 20-50 v% of a lactobacillus paracasei bacterial suspension and 50-80 v% of a plant extract, the preservation number of the lactobacillus paracasei SWFU-D16 is CCTCC (China Center for Type Culture Collection) NO: M2023709, and the lactobacillus paracasei SWFU-D16 is preserved in the China Center for Type Culture Collection on May 9, 2023. According to the present invention, the Lacticaseibacillus paracasei SWFU-D16 separated from Yunnan characteristic traditional food (dairy cake), the hawthorn, the pawpaw, the roxburgh rose, the black tea and the like are prepared into the composite beverage, and the beverage has characteristics of high nutrition value, spleen and stomach regulating, blood fat level regulating, intestinal flora regulating and other functions, and meets the requirements of people on taste, nutrition, health, health preserving and other aspects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of food processing, and in particular relates to a lactobacillus paracasei compound beverage, a preparation method and application of the lactobacillus paracasei. Background Art

[0002] Lactic acid bacteria play a very important role in human health and life. In addition to improving food flavor and texture, lactic acid bacteria also have the functions of regulating the microecological balance of intestinal flora, increasing immunity, and delaying aging. Studies have shown that lactic acid bacteria play a vital role in maintaining the microecological balance and lipid metabolism balance of the human intestine.

[0003] Some traditional fermented foods in my country contain rich lactic acid bacteria resources, which provide favorable conditions for screening lactic acid bacteria with excellent lipid-lowering function. Milk cake is a traditional food with Yunnan characteristics made from goat milk through natural fermentation. In the long-term natural domestication and process optimization process, it not only retains rich and diverse lactic acid bacteria resources, but also breeds many lactic acid bacteria strains with special biological characteristics.

[0004] With the improvement of living standards and the acceleration of the pace of life, people's energy intake has increased but the amount of exercise has been insufficient, which can easily lead to problems such as increased blood lipid levels and intestinal dysfunction. According to statistics, the prevalence of dyslipidemia in Chinese adults is 40.40%. Hyperlipidemia cannot be cured by drugs, and most drugs have certain side effects on the body, affecting people's quality of life and physical health. Summary of the invention

[0005] In order to reduce the damage of blood lipid-lowering drugs to the human body and develop non-toxic and side-effect lipid-lowering medicinal and edible foods, the present invention separates lactic acid bacteria with blood lipid-lowering effects from traditional fermented goat milk cakes, and compound them with medicinal and edible Chinese medicinal materials with the effects of strengthening the spleen and stomach, lowering blood lipids, and improving immunity, to develop nutritious, delicious, and health-care lactic acid bacteria sugar-free beverages. The specific technical solutions provided by the present invention are as follows:

[0006] In a first aspect, the present invention provides a Lactobacillus paracasei-plant extract composite beverage having a lipid-lowering effect.

[0007] Preferably, the Lactobacillus paracasei SWFU-D16 has a deposit number of CCTCC NO: M2023709, and was deposited in the China Center for Type Culture Collection on May 9, 2023.

[0008] Preferably, the compound beverage comprises 20-50v% of the Lactobacillus paracasei suspension and 50-80v% of the plant extract.

[0009] Preferably, the proportion of the Lactobacillus paracasei suspension in the composite beverage is 20v%, 25v%, 30v%, 35v%, 40v%, 45v%, 50v%, and the corresponding proportion of the plant extract is 80v%, 75v%, 70v%, 65v%, 60v%, 55v%, 50v%.

[0010] Furthermore, the compound beverage comprises 50v% of Lactobacillus paracasei suspension and 50v% of plant extract.

[0011] Preferably, the bacterial content of the Lactobacillus paracasei suspension is 1×10 8 ~1×10 9 CFU / mL.

[0012] Furthermore, the plant extract includes hawthorn extract, black tea extract, roxburghii extract and papaya extract.

[0013] Preferably, the volume fraction of the hawthorn extract is 10-30 parts, the volume fraction of the black tea extract is 30-50 parts, the volume fraction of the roxburghii extract is 10-30 parts, and the volume fraction of the papaya extract is 5-20 parts.

[0014] Preferably, the plant extract further comprises citric acid, erythritol, sucralose, pectin and carrageenan.

[0015] Preferably, in the plant extract, the concentration of citric acid is 2-5 g / L, the concentration of erythritol is 20-100 g / L, the concentration of sucralose is 0.1-0.3 g / L, the concentration of pectin is 0.1-1 g / L, and the concentration of carrageenan is 0.1-1 g / L.

[0016] In a second aspect, the present invention provides a method for preparing the composite beverage according to the first aspect, characterized in that the preparation method comprises the following steps:

[0017] Using Lactobacillus paracasei SWFU-D16 with a preservation number of CCTCC NO: M2023709 as a strain, preparing a Lactobacillus paracasei suspension;

[0018] Adding dried hawthorn into the first hot water, extracting and filtering to obtain hawthorn extract;

[0019] The roxburghii extract is prepared by adding the roxburghii into drinking water, beating the roxburghii and filtering the roxburghii;

[0020] Adding the papaya slices into the second hot water, extracting and filtering to obtain a papaya extract;

[0021] brewing the black tea with the third hot water and filtering to obtain a black tea extract;

[0022] The hawthorn extract, the roxburghii extract, the papaya extract and the black tea extract are mixed according to a first preset ratio, and then citric acid, erythritol, sucralose, pectin and carrageenan are added, and the mixture is mixed and sterilized at high temperature to obtain a plant extract;

[0023] The Lactobacillus paracasei suspension and the plant extract are mixed and homogenized according to a second preset ratio to obtain the composite beverage.

[0024] Preferably, the material-water ratio of the dried hawthorn to the first hot water is 1:20-30 (w:v), for example, 1:20, 1:22, 1:25, 1:28, 1:30.

[0025] Preferably, the temperature of the first hot water is 70-80°C, for example, 70°C, 73°C, 75°C, 78°C, 80°C.

[0026] Preferably, the first hot water extraction time is 5-10 min, for example, 5 min, 6 min, 7 min, 8 min, 9 min, 10 min.

[0027] Preferably, the material-water ratio of the roxburghii to drinking water is 1:20-30 (w:v), for example, 1:20, 1:22, 1:25, 1:28, 1:30.

[0028] Preferably, the drinking water is at room temperature.

[0029] Preferably, the material-water ratio of the papaya slices to the second hot water is 1:20-30 (w:v), for example, 1:20, 1:22, 1:25, 1:28, 1:30.

[0030] Preferably, the temperature of the second hot water is 90-95°C, for example, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C.

[0031] Preferably, the second hot water extraction time is 60-80 min, for example 60 min, 65 min, 70 min, 75 min, 80 min.

[0032] Preferably, the material-water ratio of the black tea to the third hot water is 1:60-80 (w:v), for example, 1:60, 1:65, 1:70, 1:75, 1:80.

[0033] Preferably, the third hot water temperature is 90-95°C, for example, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C.

[0034] Preferably, the brewing time is 1-3 min, for example, 1 min, 1.5 min, 2 min, 2.5 min, 3 min.

[0035] Preferably, the first preset ratio is hawthorn extract (v%): black tea extract (v%): roxburghii extract (v%): papaya extract (v%).

[0036] Furthermore, the first preset ratio is 10-30:30-50:10-30:5-20.

[0037] Preferably, in the plant extract, the concentration of citric acid is 2-5 g / L, the concentration of erythritol is 20-100 g / L, the concentration of sucralose is 0.1-0.3 g / L, the concentration of pectin is 0.1-1 g / L, and the concentration of carrageenan is 0.1-1 g / L.

[0038] Preferably, the second preset ratio is Lactobacillus paracasei suspension (v%):plant extract (v%).

[0039] Furthermore, the second preset ratio is 20-50:50-80.

[0040] In a third aspect, the present invention provides use of the compound beverage described in the first aspect in reducing blood lipids.

[0041] Preferably, the application includes at least one of the following applications:

[0042] (1) Reduce TC, TG and LDL-C and increase HDL-C;

[0043] (2) degradation of triglycerides;

[0044] (3) regulating the expression of genes related to fat metabolism in the liver, preferably LPL, PPAR-α, CYP7A1 and / or CPT1, and further, the regulation is upregulation;

[0045] (4) Improve the diversity of intestinal flora;

[0046] (5) Increase the thickness of the digestive tract mucosa.

[0047] In a fourth aspect, the present invention provides the use of Lactobacillus paracasei SWFU-D16 with a deposit number of CCTCC NO: M2023709 in the preparation of foods, health products and / or medicines capable of reducing blood lipids.

[0048] Preferably, the application has the same content as the application of the third aspect.

[0049] Preferably, the food further comprises auxiliary materials permitted to be added to foods.

[0050] Preferably, the health care product further includes auxiliary materials allowed to be added to health care products.

[0051] Preferably, the feed further comprises auxiliary materials allowed to be added to feed.

[0052] Preferably, the medicine further includes excipients allowed to be added to medicines.

[0053] In a fifth aspect, the present invention provides the use of a Lacticaseibacillus paracasei SWFU-D16 bacterial suspension in the preparation of food, health products, feed and / or medicine having the function of lowering blood lipids.

[0054] Preferably, the application has the same content as the application of the third aspect.

[0055] Preferably, the food further comprises auxiliary materials permitted to be added to foods.

[0056] Preferably, the health care product further includes auxiliary materials allowed to be added to health care products.

[0057] Preferably, the feed further comprises auxiliary materials allowed to be added to feed.

[0058] Preferably, the medicine further includes excipients allowed to be added to medicines.

[0059] Beneficial effects of the present invention:

[0060] The Lactobacillus paracasei SWFU-D16 in the present invention is separated from a traditional food (milk cake) with Yunnan characteristics. Compared with existing lactic acid strains, SWFU-D16 has a stronger effect of reducing blood lipids and restoring intestinal microbial species.

[0061] Beverages made from SWFU-D16 and hawthorn, papaya, sea buckthorn, black tea, etc. have high nutritional value, and the compound beverage has the functions of regulating the spleen and stomach, regulating blood lipid levels and intestinal flora, etc., meeting people's needs in terms of taste, nutrition, health, and wellness. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 The effect of SWFU-D16 on body weight and Lee's index of high-fat mice;

[0063] Figure 2 This is the fat vacuoles in the liver cells of high-fat mice;

[0064] Figure 3It is the fatty degeneration in the liver tissue cells of high-fat mice;

[0065] Figure 4 The effect of SWFU-D16 on the mRNA expression levels of fat metabolism-related genes LPL, PPAR-α, CYP7A1, CPT1 and PPAR-γ in the liver tissue of high-fat mice;

[0066] Figure 5 The effect of SWFU-D16 on the Alpha diversity index of intestinal flora in high-fat mice;

[0067] Figure 6 The effect of SWFU-D16 on the species classification system in the intestine of high-fat mice;

[0068] Figure 7 The effect of SWFU-D16 on the taxonomic clades of species in the intestine of high-fat mice;

[0069] Figure 8 The effect of SWFU-D16 on the LDA value of intestinal species in high-fat mice;

[0070] Fig. 9 Effects of the composite beverage on the expression of adipogenic genes in 3T3-L1 preadipocytes.

[0071] The strain of the present invention is deposited on May 9, 2023, and the deposit number is: CCTCC NO: M2023709. The classification name is: Lactobacillus paracasei SWFU-D16, the depository name is China Center for Typical Microorganisms, the address is Wuhan University, China, zip code 430072. DETAILED DESCRIPTION

[0072] The technical solution of the present invention is further described below in conjunction with the embodiments and drawings, and the advantages and features of the present invention will become clearer with the description. However, it should be understood that the embodiments are only exemplary and do not limit the scope of the present invention.

[0073] It should be noted that the experimental methods used in the following examples are conventional methods in the art unless otherwise specified.

[0074] Example 1 Effect of SWFU-D16 on blood lipids in mice

[0075] 1.1 Culture of SWFU-D16

[0076] After the preserved SWFU-D16 strain was activated, it was inoculated into MRS liquid medium at a 1% inoculum and cultured at 37°C to obtain a bacterial count of 2.0×10 11 CFU / mL of bacterial suspension.

[0077] 1.2 Mouse feeding experiment

[0078] 72 mice weighing 20 g were randomly divided into 6 groups, namely control group, model group, low-dose group, medium-dose group, high-dose group and drug group. The control group was fed with low-fat control feed and normal saline, the model group was fed with 60% high-fat model feed and normal saline; the low-dose group was fed with 60% high-fat model feed and 1×10 8 CFU / mL SWFU-D16 in normal saline; the medium-dose group was fed with 60% high-fat model feed and 1×10 9 CFU / mL SWFU-D16 in normal saline; the high-dose group was fed with 60% high-fat model feed and 1×10 10 CFU / mL SWFU-D16 in normal saline; the drug group was fed with 60% high-fat model feed and cholestyramine powder (1 g / kg).

[0079] Table 1 Animal feed formula

[0080]

[0081] Table 2 Animal experiment groups

[0082]

[0083] Each group had free access to water. The mice were gavaged every morning in the above manner. The gavage volume was 0.4 mL per mouse. The daily food intake and weekly body weight were recorded. After a feeding cycle of 10 weeks, the mice in each group were anesthetized by intraperitoneal injection of sodium pentobarbital, and then blood was collected from the heart, and feces and liver were taken from the intestines. The following analyses were performed:

[0084] The liver, heart, kidney, spleen, perirenal fat and epididymal fat of the mice were taken and weighed, and the organ index of the mice was calculated. Figure 1 .

[0085] Depend on Figure 1 It can be seen that the weight of mice in the high-fat model group, SWFU-D16 low-dose group, SWFU-D16 medium-dose group, SWFU-D16 high-dose group, and drug group were all higher than those in the control group, indicating that the mouse high-fat model was successfully constructed. Compared with the high-fat model group, the weight of mice in the SWFU-D16 low-dose group, SWFU-D16 medium-dose group, and SWFU-D16 high-dose group decreased with the increase in the dose of SWFU-D16, and the difference reached a significant level. There was no significant difference in the weight of mice in the SWFU-D16 medium-dose group and the SWFU-D16 high-dose group and the drug group. This shows that SWFU-D16 can effectively reduce the weight of mice and can achieve the same effect as the drug.

[0086] In addition, the Lee's index of mice in the model group, low-dose SWFU-D16 lactic acid bacteria group, medium-dose SWFU-D16 group, drug group, and high-dose SWFU-D16 group decreased in turn. The differences between the medium-dose SWFU-D16 group, high-dose SWFU-D16 group, and drug group and the model group reached a significant level, and the difference between the high-dose SWFU-D16 group and the drug group was close to a significant level, indicating that oral administration of lactic acid bacteria SWFU-D16 can reduce the growth of body fat in mice under high-fat diet conditions.

[0087] The morphology of the liver and epididymal fat of mice was observed under an optical microscope. Figure 2 and Figure 3 . The liver tissue of mice in the high-fat model group showed microvesicular fatty degeneration and high fat content. A large number of fat vacuoles were observed around the blood vessels, which caused cell swelling and destroyed the integrity of the cell membrane. After intervention with SWFU-D16, the fatty degeneration of the mouse liver tissue was alleviated, the fat vacuoles in the hepatocytes decreased, and the cell morphology was similar to that of the control group. The epididymal adipocytes of mice in the high-fat model group were large and had thin cell membranes. The epididymal adipose tissue of mice treated with lactic acid bacteria SWFU-D16 was denser than that of the model group, and the average size of the adipocytes was similar to that of the control group. This shows that lactic acid bacteria SWFU-D16 can reduce the degeneration and hypertrophy of adipocytes caused by a high-fat diet.

[0088] The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) in mouse serum were determined. The results are shown in Table 3.

[0089] Table 3 Mouse serum biochemical indexes

[0090]

[0091] As can be seen from Table 3, the TC, TG and LDL-C of the high-fat model group, SWFU-D16 low-dose group, SWFU-D16 medium-dose group, and SWFU-D16 high-dose group were higher than those of the control group, and the HDL-C was lower than that of the control group, indicating that the mouse high-fat model was successfully established. Compared with the high-fat model group, the TC, TG and LDL-C of the SWFU-D16 low-dose group, SWFU-D16 medium-dose group, and SWFU-D16 high-dose group decreased with the increase of SWFU-D16 dose, while HDL-C increased with the increase of SWFU-D16 dose. The difference between the TC of the SWFU-D16 low-dose group, SWFU-D16 medium-dose group, SWFU-D16 high-dose group, and drug group and the TC of the model group reached a significant level, and the difference between the SWFU-D16 low-dose group, SWFU-D16 medium-dose group and the drug group was not obvious, but the difference between the SWFU-D16 high-dose group and the drug group reached a significant level. The difference between TG of SWFU-D16 medium-dose group, SWFU-D16 high-dose group, and drug group and TG of model group reached a significant level, and the difference between SWFU-D16 high-dose group and drug group was not significant. The difference between LDL-C of SWFU-D16 low-dose group, SWFU-D16 medium-dose group, SWFU-D16 high-dose group, and drug group and LDL-C of model group reached a significant level, and the difference between SWFU-D16 medium-dose group, SWFU-D16 high-dose group and drug group was not significant. The difference between HDL-C of SWFU-D16 medium-dose group, SWFU-D16 high-dose group, and drug group and HDL-C of model group reached a significant level, and the difference between SWFU-D16 high-dose group and drug group was significant. It shows that SWFU-D16 can effectively reduce blood lipid levels in mouse serum and play a role in reducing obesity.

[0092] The expression of genes related to fat metabolism in mouse liver was analyzed. The results are shown in Figure 4 .

[0093] Depend on Figure 4It can be seen that compared with the high-fat model group, the mRNA expression levels of LPL, PPAR-α, CYP7A1 and CPT1 in the liver of mice in the SWFU-D16 low-dose group, SWFU-D16 medium-dose group and SWFU-D16 high-dose group increased with the increase of SWFU-D16 dose, while the expression level of PPAR-γ decreased with the increase of SWFU-D16 dose. PPAR is a ligand-activated receptor in the nuclear hormone receptor family and is involved in the physiological processes of various diseases including obesity. Among them, PPAR-α plays an important role in maintaining the lipid metabolism of organisms; SWFU-D16 intervention upregulated the expression level of PPAR-α in mice in the high-fat model group, indicating that lactic acid bacteria SWFU-D16 can normalize the transport and oxidation of free fatty acids and reduce lipid accumulation; PPAR-γ regulates the proliferation and differentiation of adipocytes. SWFU-D16 intervention downregulated the expression level of PPAR-γ, indicating that lactic acid bacteria SWFU-D16 can reduce the proliferation and differentiation of adipocytes and make them close to normal mice. CPT1 is a critical rate-limiting enzyme in the process of fatty acid oxidation, and changes in its level are closely related to the development of obesity. SWFU-D16 intervention upregulated the expression level of CPT1, indicating that lactic acid bacteria SWFU-D16 can promote fatty acid oxidation metabolism in mice. LPL is a key enzyme in lipid metabolism. Its increased expression level can increase the level of high-density lipoprotein cholesterol in the body's serum and reduce the cholesterol content. SWFU-D16 intervention upregulated the expression level of LPL in mice in the high-fat model group, indicating that SWFU-D16 regulates and inhibits the increase of serum cholesterol in mice by affecting the expression of LPL. CYP7A1 is a rate-limiting enzyme for the synthesis of bile acid, which can catalyze the decomposition of cholesterol into bile acid in the liver and prevent obesity. SWFU-D16 intervention upregulated the expression of the CYP7A1 gene in mice in the high-fat model group, indicating that SWFU-D16 can promote the decomposition of cholesterol and reduce the weight of mice. Therefore, the mRNA regulation level of the SWFU-D16 group is close to or exceeds that of the drug group, indicating that the lipid-lowering effect of SWFU-D16 is very significant.

[0094] The intestinal microbiota of mice was analyzed and the results are shown in Figure 5-Figure 8 .

[0095] Depend on Figure 5 It can be seen that the Chao, observed species and Shannon index of high-fat fed mice are relatively low, and the larger the Shannon index, the higher the community diversity, indicating that a high-fat diet will reduce the abundance of microorganisms in the intestines of mice, while the abundance of lactic acid bacteria SWFU-D16 has a slight upward trend after oral administration, indicating that the intake of lactic acid bacteria SWFU-D16 increases the diversity of intestinal flora.

[0096] Depend on Figure 6 It can be seen that the microorganisms at the genus level in the intestines of the six groups of mice are mainly Ruminiclostridium_9, Helicobacter, Akkermansia spp, Bacteroides and Desulfovibrio. Among them, the relative abundance of Verrucomicrobia was significantly increased after the intervention of lactic acid bacteria SWFU-D16. This shows that lactic acid bacteria SWFU-D16 prevents harmful substances from passing through the digestive tract by increasing the thickness of the mouse digestive tract mucosa, thereby preventing hyperlipidemia.

[0097] like Figure 7 and Figure 8 As shown, the biomarkers with LDAScore greater than 5 are Firmicutes, Clostridia, Clostridiales, Bacteroidetes, Bacteroidia, and Bacteroidales.

[0098] Example 2 Preparation of compound beverage sample 1

[0099] 2.1 Culture of SWFU-D16

[0100] The specific culture process is the same as 1.1 in Example 1.

[0101] 2.2 Preparation of plant extracts

[0102] 2.2.1 Grind the dried hawthorn into powder, extract it with 75℃ hot water for 7 minutes at a material-water ratio of 1:25 (w:v), and filter to obtain the hawthorn extract.

[0103] 2.2.2 Add fresh sea buckthorn to drinking water at room temperature at a material-water ratio of 1:25 (w:v), beat and filter to obtain the sea buckthorn extract.

[0104] 2.2.3 Soak the Chinese herbal medicine papaya slices in a constant temperature water bath at a material-water ratio of 1:25 (w:v) at 95°C for 70 minutes, cool and filter to obtain the papaya extract.

[0105] 2.2.4 Brew Dianhong tea leaves with 95℃ hot water at a ratio of 1:70 (w:v) for 2 minutes, then filter to obtain black tea extract.

[0106] 2.2.5 The SWFU-D16 bacterial suspension prepared in Experiment 2.1 was diluted 10-fold to obtain a viable bacterial count of 1×10 9 CFU / mL of SWFU-D16 bacterial suspension.

[0107] 2.2.6 First, mix 20 parts of hawthorn extract, 40 parts of black tea extract, 20 parts of roxburghii extract and 10 parts of papaya extract according to the volume ratio, and then add citric acid, erythritol, sucralose, pectin and carrageenan to the mixture at concentrations of 3g / L, 50g / L, 0.15g / L, 0.75g / L and 0.4g / L respectively. After mixing evenly again, sterilize at 90℃ for 30s, and then cool to room temperature for use.

[0108] 2.2.7 Take the sterilized plant extract according to the ratio in Table 4 and add 1×10 9 The SWFU-D16 bacterial suspension with a CFU / mL was mixed evenly to prepare a lactic acid bacteria composite beverage sample.

[0109] Table 4 Compound beverage ratio

[0110]

[0111] 2.2.8 The lipid-lowering ability of the compound beverages No. 1 to 6 prepared in 2.2.7 was determined using a triglyceride kit. 2.0% polyvinyl alcohol solution and vegetable oil treated with ultrasound were added to the sample solution as triglyceride sources and mixed evenly, and then the working solution was added. The mixture was kept at 37°C for 10 minutes, and the blank tube was used for zero calibration. The absorbance value was measured at 500nm, and the degradation rate of triglycerides was calculated. At the same time, the color, flavor, texture, etc. of the compound beverages No. 1 to 6 were sensory evaluated. The results are shown in Table 5.

[0112] Table 5 Lipid reduction rate and sensory scores of compound beverages

[0113]

[0114] As shown in Table 5, compound beverage sample 3 has significantly stronger lipid-lowering ability, is light brown in color, has unique aromas and flavors of hawthorn, sea buckthorn and black tea, has a sweet and sour taste, and has a comprehensive weighted score that is significantly better than other formulas.

[0115] Example 3 Preparation of composite beverage comparison sample

[0116] The specific experimental process is the same as that of the composite beverage sample 3 in Example 2, except that SWFU-D16 is replaced by Lactobacillus plantarum (ATCC 8014).

[0117] Example 4 Effect of compound beverage on adipogenic genes in 3T3-L1 preadipocytes

[0118] After thawing, medium replacement and subculturing, 3T3-L1 preadipocytes were cultured at 2×10 4The cells were inoculated into a 24-well plate at a density of cells / well and cultured until the cell density reached more than 90%. Pre-adipocytes were induced with MDI medium for 2 days. 10 μL of water, compound beverage sample 3, compound beverage sample 4, SWFU-D16 bacterial suspension, medicinal and edible plant extract and sample of Example 3 were added to each well respectively. The cells were then maintained in a basal medium with 10 μg / mL insulin added, and the medium was renewed every 2 days. The induction lasted until the 8th day when obvious lipid droplet formation was observed. RNA was extracted and cDNA was synthesized. Fluorescence quantitative PCR was used to analyze the changes in fat synthesis and differentiation genes of 3T3-L1 cells. The results are shown in Fig. 9 .

[0119] The process of preadipocyte differentiation and adipocyte formation is affected by the fat differentiation-related factors C / EBPα and C / EBPβ, and is also related to the lipid metabolism genes acetyl coenzyme a carboxylase (ACC) and fatty acid synthase (FAS). Lipid-lowering drugs or foods often inhibit 3T3-L1 preadipocyte differentiation by inhibiting fat differentiation and production. Fig. 9 As shown, the five test groups can reduce the expression of fat differentiation genes C / EBPα, C / EBPβ and fat generation genes FAS, ACC. Compared with the composite beverage sample 4, SWFU-D16 bacterial suspension, medicinal and edible plant extract and the composite beverage sample of Example 3, the composite beverage sample 3 has a significantly better effect on reducing the expression of the four genes. It shows that the Lactobacillus paracasei SWFU-D16-medical and edible plant composite beverage derived from milk cake prepared by the present invention has a strong lipid-lowering effect.

[0120] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent structural transformations made using the contents of the present invention specification, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A Lactobacillus paracasei-plant extract composite beverage with blood lipid lowering effect, characterized in that: The composite beverage comprises 20-50v% of a Lactobacillus paracasei suspension and 50-80v% of a plant extract; The Lactobacillus paracasei SWFU-D16 has a preservation number of CCTCCNO: M2023709 and was preserved in the China Center for Type Culture Collection on May 9, 2023.

2. The compound beverage according to claim 1, characterized in that: The compound beverage comprises 20-50v% of the lactobacillus paracasei suspension and 50-80v% of the plant extract.

3. The compound beverage according to claim 3, characterized in that: The compound beverage comprises 50v% of the Lactobacillus paracasei suspension and 50v% of the plant extract.

4. The composite beverage according to any one of claims 1 to 3, characterized in that: The bacterial content of the Lactobacillus paracasei suspension is 1×10 8 ~1×10 9 CFU / mL.

5. The compound beverage according to any one of claims 1 to 3, characterized in that: The plant extract comprises, by volume, 10-30 parts of hawthorn extract, 30-50 parts of black tea extract, 10-30 parts of roxburghii extract and 5-20 parts of papaya extract.

6. The compound beverage according to claim 5, characterized in that: The plant extract also includes citric acid, erythritol, sucralose, pectin and carrageenan; The concentration of the citric acid is 2-5 g / L, the concentration of the erythritol is 20-100 g / L, the concentration of the sucralose is 0.1-0.3 g / L, the concentration of the pectin is 0.1-1 g / L, and the concentration of the carrageenan is 0.1-1 g / L.

7. A method for preparing a Lactobacillus paracasei-plant extract composite beverage with a lipid-lowering effect, characterized in that: The preparation method comprises the following steps: Using Lactobacillus paracaseiSWFU-D16 with a preservation number of CCTCC NO: M2023709 as a bacterial species, a Lactobacillus paracasei suspension was prepared; Adding dried hawthorn into the first hot water, extracting and filtering to obtain hawthorn extract; The roxburghii extract is prepared by adding the roxburghii into drinking water, beating the roxburghii and filtering the roxburghii; Adding the papaya slices into the second hot water, extracting and filtering to obtain a papaya extract; brewing the black tea with the third hot water and filtering to obtain a black tea extract; The hawthorn extract, the roxburghii extract, the papaya extract and the black tea extract are mixed according to a first preset ratio, and then citric acid, erythritol, sucralose, pectin and carrageenan are added, and the mixture is mixed and sterilized at high temperature to obtain a plant extract; The Lactobacillus paracasei suspension and the plant extract are mixed and homogenized according to a second preset ratio to obtain the composite beverage.

8. The preparation method according to claim 7, characterized in that: The material-water ratio of the dried hawthorn to the first hot water is 1:20-30 (w:v), the temperature of the first hot water is 70-80° C., and the first hot water extraction time is 5-10 min; The material-water ratio of the roxburghii to drinking water is 1:20-30 (w:v), and the temperature of the drinking water is room temperature; The material-water ratio of the papaya slices to the second hot water is 1:20-30 (w:v), the temperature of the second hot water is 90-95° C., and the second hot water extraction time is 60-80 min; The material-water ratio of the black tea to the third hot water is 1:60-80 (w:v), the temperature of the third hot water is 90-95° C., and the brewing time is 1-3 min.

9. Use of the compound beverage according to any one of claims 1 to 6 in reducing blood lipids.

10. Use of Lactobacillus paracasei SWFU-D16 with a deposit number of CCTCC NO: M2023709 in the preparation of food, health products, feed and / or medicine for lowering blood lipids.